


Technology Advisory Committee D Interests Register

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum


based chemotherapy [ID3735]

Publication Date: 11 June 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Alison Birtle	Clinical expert	Direct - Financial	Dr Birtle has received advisory board and speaker fees from Astellas, Bayer, BMS, Pfizer and Sanofi-Genzyme and speaker fees from Janssen Pharmaceutical, Merck Sharp & Dohme and Roche. She has provided educational support to Janssen Pharmaceutical and received research support from Sanofi-Genzyme.	N/A	16.10.2020	N/A	It was agreed that this declaration would not prevent Dr Birtle from providing expert advice to the committee.
Professor Syed A Hussain	Clinical expert	Direct - Financial	Professor Hussain has received research funding from CR UK, MRC/NIHR, UHB charities, CCC charities, North West Cancer Research, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre	N/A	24.08.2020	N/A	It was agreed that this declaration would not prevent Professor Hussain from providing expert advice to the committee.



			and Eli Lilly and attended advisory boards and received consultancy fees from Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Pierre Fabre, Ipsen and Sotio.				
Mr Kevin Gorman	Patient expert	Indirect - Financial	Mr Gorman is a Trustee of Action Bladder Cancer UK. Action Bladder Cancer UK has received contributions from Merck and other companies to help compensate for loss of general income during the coronavirus pandemic.	N/A	20.08.2020 10.02.2022	N/A	It was agreed that this declaration would not prevent Mr Gorman from providing expert advice to the committee.
Dr Lydia Makaroff	Patient expert	Indirect - Financial	Dr Makaroff is an employee of Fight Bladder Cancer. Fight Bladder Cancer has received financial support from F. Hoffman-La Roche AG, Bristol-Myers Squibb, Janssen Pharmaceutica, Merck KgaA, MSD and Pfizer. Fight Bladder Cancer received a £1,000 Honorarium from Merck Healthcare KGaA.for expert input provided	N/A	17.08.2020	N/A	It was agreed that this declaration would not prevent Dr Makaroff from providing expert advice to the committee.



during the Virtual Global Patient Advisory Board on Bladder Cancer on 9th July 2020.
Dr Makaroff is a volunteer board member of the World Bladder Cancer Patient Coalition. The World Bladder Cancer Patient Coalition has received financial support from F. Hoffman-La Roche AG, AstraZeneca, Bayer AG, Astellas Pharma, Bristol-Myers Squibb, Ipsen, Janssen Pharmaceutica, Merck KgaA, MSD, Pfizer, Photocure and Seattle Genetics.